As of June 2, 2025, Xphyto Therapeutics Corp (XPHY.CN) reports a Current Ratio of 0.50.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Xphyto Therapeutics Corp's Current Ratio
Over recent years, Xphyto Therapeutics Corp's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2021-12-31 | 0.50 |
| 2020-12-31 | 2.07 |
| 2019-12-31 | 0.52 |
| 2018-12-31 | 5.35 |
| 2017-12-31 | 5.57 |
This gradual decrease highlights how Xphyto Therapeutics Corp manages its short-term assets and liabilities over time.
Comparing Xphyto Therapeutics Corp's Current Ratio to Peers
To better understand Xphyto Therapeutics Corp's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Xphyto Therapeutics Corp (XPHY.CN) | 0.50 |
| Chiasma Inc (CHMA) | 9.19 |
| scPharmaceuticals Inc (SCPH) | 7.12 |
| Odonate Therapeutics Inc (ODT) | 5.90 |
| Cocrystal Pharma Inc (COCP) | 4.77 |
| Cardiol Therapeutics Inc (CRDL.TO) | 4.52 |
Compared to its competitors, Xphyto Therapeutics Corp's Current Ratio is among the lowest compared to peers, suggesting tighter liquidity management or potential short-term obligations concerns.